Transcranial Magnetic Treatment (TMS) in Unipolar Depression
NCT ID: NCT00186784
Last Updated: 2011-08-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
21 participants
INTERVENTIONAL
2000-12-31
2011-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, the investigators seek to increase their understanding about how rTMS improves depression, and to determine which form of rTMS is most effective for depression, when used in combination with antidepressant medication.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Transcranial Magnetic Stimulation in Bipolar Depression
NCT00186758
Transcranial Magnetic Stimulation in Depression
NCT00018746
rTMS and Cognitive Training in Youth Depression
NCT03708172
Using Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Bipolar Depression
NCT01583023
Repetitive Transcranial Magnetic Stimulation Trajectory of Outcomes Study
NCT04376697
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Magnetic Stimulation (TMS)
treatment for 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* No physical health problems
Exclusion Criteria
* Metal in the head/neck or skull
* Pacemaker
* Pregnancy
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Queen's University, Kingston, Ontario
OTHER
St. Joseph's Healthcare Hamilton
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
St. Joseph's Healthcare
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary Hasey, MD
Role: PRINCIPAL_INVESTIGATOR
McMaster University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St.Joseph's Healthcare, rTMS Laboratory, Mood Disorders Program, 100 West Fifth Street
Hamilton, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Jacquot F, Khoury S, Labrum B, Delanoe K, Pidoux L, Barbier J, Delay L, Bayle A, Aissouni Y, Barriere DA, Kultima K, Freyhult E, Hugo A, Kosek E, Ahmed AS, Jurczak A, Lingueglia E, Svensson CI, Breuil V, Ferreira T, Marchand F, Deval E. Lysophosphatidylcholine 16:0 mediates chronic joint pain associated to rheumatic diseases through acid-sensing ion channel 3. Pain. 2022 Oct 1;163(10):1999-2013. doi: 10.1097/j.pain.0000000000002596. Epub 2022 Jan 27.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TMS1871
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.